Trial Profile
Phase II study of DEBIRI and capecitabine in refractory prevalently liver metastases of colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2015 New trial record